Skip to main content

Advertisement

Table 1 Antimicrobial activity of antimicrobial agents against Enterobacteriaceae collected globally between 2004 - 2013

From: Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

  MIC 90 (mg/L) MIC range mg/L % susceptible % resistant
Enterobacteriaceae (n = 118,899)     
AMK 8 ≤0.5 – ≥ 128 96.9 1.8
AMC ≥64 ≤0.12 – ≥ 64 43.5 46.2
AMP (n = 118,648) ≥64 ≤0.5 – ≥ 64 13.0 80.4
FEP 16 ≤0.5 – ≥ 64 88.7 8.8
CRO 64 ≤0.06 – ≥ 128 72.3 25.7
IPM (n = 25,381) 1 ≤0.06 – ≥ 32 97.1 0.9
LVX ≥16 ≤0.008 – ≥ 16 79.0 18.4
MEM (n = 93,518) 0.25 ≤0.06 – ≥ 32 97.0 2.3
MIN 16 ≤0.5 – ≥ 32 74.9 13.1
TZP 64 ≤0.06 – ≥ 256 84.0 9.4
TGC 1 ≤0.008 – ≥ 32 97.0 0.6
Enterobacteriaceae, MDR (n = 9,372)     
AMK ≥128 ≤0.5 – ≥ 128 75.4 17.8
AMC ≥64 0.25 – ≥ 64 11.8 67.8
AMP (n = 9,371) ≥64 ≤0.5 – ≥ 64 0.2 99.5
FEP ≥64 ≤0.5 – ≥ 64 47.3 44.2
CRO ≥128 ≤0.06 – ≥ 128 20.3 78.2
IPM (n = 1,158) 4 ≤0.06 – ≥ 32 85.2 12.1
LVX ≥16 ≤0.008 – ≥ 16 6.1 92.1
MEM (n = 8,214) ≥32 ≤0.06 – ≥ 32 75.3 21.8
MIN ≥32 ≤0.5 – ≥ 32 12.0 81.5
TZP ≥256 ≤0.06 – ≥ 256 39.5 44.0
TGC 4 ≤0.008 – ≥ 32 83.2 6.9
  1. AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MDR, multidrug-resistant; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin.